$2.62
8.07% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US09203E1055
Symbol
BDTX
Sector
Industry

Black Diamond Therapeutics Inc Stock price

$2.62
-0.78 22.94% 1M
-2.82 51.84% 6M
-0.19 6.76% YTD
+0.37 16.44% 1Y
-5.03 65.75% 3Y
-36.86 93.36% 5Y
-36.86 93.36% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.23 8.07%
ISIN
US09203E1055
Symbol
BDTX
Sector
Industry

Key metrics

Market capitalization $148.25m
Enterprise Value $58.57m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 1.52
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-81.36m
Cash position $112.68m
EPS (TTM) EPS $-1.36
P/E forward negative
Short interest 18.82%
Show more

Is Black Diamond Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Black Diamond Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Black Diamond Therapeutics Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Black Diamond Therapeutics Inc forecast:

Buy
100%

Financial data from Black Diamond Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.34 0.34
90% 90%
-
-0.34 -0.34
90% 90%
-
- Selling and Administrative Expenses 27 27
5% 5%
-
- Research and Development Expense 54 54
3% 3%
-
-81 -81
4% 4%
-
- Depreciation and Amortization 0.34 0.34
90% 90%
-
EBIT (Operating Income) EBIT -81 -81
7% 7%
-
Net Profit -73 -73
13% 13%
-

In millions USD.

Don't miss a Thing! We will send you all news about Black Diamond Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Black Diamond Therapeutics Inc Stock News

Neutral
GlobeNewsWire
11 days ago
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.
Neutral
GlobeNewsWire
15 days ago
CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., ar...
Neutral
Seeking Alpha
about one month ago
Preliminary results from phase 2 study using BDTX-1535 for the treatment of 1st-line EGFRm NSCLC patients, expected in Q1 of 2025. Updated cohort results from the phase 2 study using BDTX-1535 for the treatment of 2nd-line/3rd-line EGFRm NSCLC patients, expected in Q1 of 2025. Company to meet with the FDA in Q1 of 2025 and provide update on possible registration study to move BDTX-1535 program ...
More Black Diamond Therapeutics Inc News

Company Profile

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Head office United States
CEO Mark Velleca
Employees 54
Founded 2014
Website www.blackdiamondtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today